Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phosphatidylserine + curcumin
- Development stage
- Preclinical
- Lead developer
- Pharmin USA
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Phosphatidylserine + curcumin (also known as PSL-Cur or PSLs-Cur) is an investigational liposomal combination formulation developed by Pharmin USA. It consists of phosphatidylserine liposomes encapsulating curcumin, a natural polyphenol extracted from turmeric (*Curcuma longa*). This formulation is designed to enhance the oral bioavailability of curcumin, which typically suffers from poor gastrointestinal absorption. Preclinical studies in rat models of glucocorticoid-induced osteoporosis have demonstrated that the combination significantly improves bone serum markers, mechanical strength, osteoprotegerin (OPG) gene expression, and cortical/trabecular bone mass, showing superior efficacy compared to alendronate. Its mechanism of action involves the inhibition of inflammatory mediators such as COX-1, COX-2, TNF, and lipoxygenase, alongside the modulation of bone remodeling pathways.
- Other names
- phosphatidylserine liposome-curcuminphosphatidylserine liposomes containing curcuminPSL-CurPSLs-Cur
02
Targets
ALOX5 (Arachidonate 5-lipoxygenase)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on phosphatidylserine + curcumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phosphatidylserine + curcumin.